Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue from new drugs and other products in Japan declined due to the impact of the drug price revision, including a reduction in the 4% range for KYORIN Pharmaceutical Co.,Ltd. Revenue from overseas new drugs declined due to a decrease following the previous year's increase in income related to gatifloxacin. The decline in revenue reduced gross profit, while selling, general and administrative expenses and research and development expenses increased.
No applicable matters (There are no applicable matters.)
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥29,654 million (YoY -1.9%) |
| Operating profit | ¥964 million (YoY -59.3%) |
| Ordinary income | ¥1,241 million (YoY -52.7%) |
| Profit attributable to owners of the parent | ¥824 million (YoY -60.8%) |
| Net income per share | ¥14.35 |
| Equity ratio | End of the current fiscal period 74.4 / End of previous period 72.9 |
| Total assets | ¥188,609 million |
| Net assets | ¥140,304 million |
| Full-year earnings forecast | Net Sales ¥121,800 million (YoY -3.5%) / Operating profit ¥2,000 million (YoY -43.9%) / Ordinary income ¥2,300 million (YoY -42.9%) / Net income ¥1,500 million (YoY -56.5%) |
| Annual Dividend Forecast | ¥57 → ¥25（-56.1%） |
| Depreciation and amortization | ¥1,144 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million, Subsidy Income ¥100 million / Extraordinary loss Loss on disposal and sale of non-current assets ¥0 million, Loss on sale of investment securities ¥1 million, Impairment loss on investment securities ¥152 million |
| Disclosure regarding the going concern assumption | No applicable matters (There are no applicable matters.) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 59,945,641 Shares |
| Treasury Shares at Period-End | 2,499,370 Shares |
| Factors Behind Changes in Business Performance | Revenue from new drugs and other products in Japan declined due to the impact of the drug price revision, including a reduction in the 4% range for KYORIN Pharmaceutical Co.,Ltd. Revenue from overseas new drugs declined due to a decrease following the previous year's increase in income related to gatifloxacin. The decline in revenue reduced gross profit, while selling, general and administrative expenses and research and development expenses increased. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to the impact of the drug price revision, including a reduction in the 4% range for KYORIN Pharmaceutical Co.,Ltd., and a decline in overseas gatifloxacin-related income following the previous year's increase. Gross profit decreased by ¥1,083 million. In addition, selling, general and administrative expenses increased by ¥321 million, while research and development expenses increased by ¥390 million.